Xcout Intel
IO Biotech, Inc.
IO Biotech, Inc. is a clinical-stage biopharmaceutical company that develops novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines. Its proprietary T-win® technology is designed to modulate the tumor microenvironment by targeting both tumor cells and immune-suppressive cells, aiming to improve treatment outcomes for patients with melanoma and other tumor types.
Subscribe to see IO Biotech, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
IO Biotech, Inc. at a glance
IO Biotech, Inc. is a biotechnology company headquartered in United States. Xcout tracks 11 named people at IO Biotech, Inc., including Amy Sullivan (Chief Financial Officer).
IO Biotech, Inc. leadership
- Amy SullivanChief Financial Officer
- Eric FaulknerChief Technical Officer
- Faiçal MiyaraChief Business Officer
- Qasim AhmadChief Medical Officer
- Devin SmithGeneral Counsel
- Mai-Britt ZoccaMember – Founder, President and Chief Executive Officer
5 more named people on record for IO Biotech, Inc., with roles, board committees and tenure — see the full roster →
IO Biotech, Inc. competitors
A few of IO Biotech, Inc.'s closest competitors — see the full list of competitors and alternatives →
ImmunityBio, Inc. is a public clinical-stage immunotherapy company headquartered in San Diego, California. As a member of the NantWorks ecosystem, it focuses on developing next-generation cancer vaccines and immunotherapies.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Irazu Oncology, LLC is a biotechnology company that develops cancer immunotherapies utilizing bacterial outer membrane vesicles. The company creates off-the-shelf treatments designed to activate anti-tumor immune responses through a scalable manufacturing process, aiming to provide more accessible and affordable therapeutic options for cancer patients.
Imvax, Inc. is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing personalized, whole-cell immunotherapies for the treatment of various cancers.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with an additional office in Belgium. The company focuses on discovering and developing novel immuno-oncology therapeutics for cancer treatment.
OSE Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for immune activation and regulation in immuno-oncology and immuno-inflammation. The company utilizes proprietary research platforms and a portfolio of clinical-stage assets to provide therapeutic options for patients.
Get IO Biotech, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on IO Biotech, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access